Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Supply, Demand and Key Producers, 2024-2030

Page: 115

Published Date: 15 Nov 2024

Category: Service & Software

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size is expected to reach $ 553 million by 2030, rising at a market growth of 19.0% CAGR during the forecast period (2024-2030).

Live Biotherapeutic Products (LBPs) are biotherapeutic products based on live microorganisms that are intended to treat or prevent disease by modulating the microbiome. These products are usually prepared from specific strains of microorganisms that have potential therapeutic effects, such as improving gut health, boosting the immune system, or reducing inflammation.The rising importance of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth.CDMOs specializing in these fields have the expertise and infrastructure to support developing and manufacturing these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.

This report studies the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service total market, 2019-2030, (USD Million)
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service total market, key domestic companies, and share, (USD Million)
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue by player, revenue and market share 2019-2024, (USD Million)
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service total market by Type, CAGR, 2019-2030, (USD Million)
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service total market by Application, CAGR, 2019-2030, (USD Million)
This report profiles major players in the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market, Segmentation by Type
    Solid Dosage Form
    Liquid Dosage Form

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market, Segmentation by Application:
    Digestive System Diseases
    Immune System Diseases
    Metabolic Diseases
    Other

Companies Profiled:
    Lallemand Health Solutions
    Wacker Chemie AG
    Biose Industrie
    List Biological Labs, Inc.
    NIZO
    SGS (Quay Pharmaceuticals)
    Assembly Biosciences, Inc.
    Recipharm (Arranta Bio)
    Bacthera (Novonesis+Lonza)
    Smaltis
    Lonza
    vermicon AG

Key Questions Answered
1. How big is the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market?
2. What is the demand of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market?
3. What is the year over year growth of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market?
4. What is the total value of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market?
5. Who are the Major Players in the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction
    1.2 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Total Market by Region (by Headquarter Location)
        1.3.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.3 China Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.4 Europe Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.5 Japan Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.6 South Korea Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.7 ASEAN Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
        1.3.8 India Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Major Market Trends

2 Demand Summary
    2.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.2 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region
        2.2.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2019-2024)
        2.2.2 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Forecast by Region (2025-2030)
    2.3 United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.4 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.5 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.6 Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.7 South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.8 ASEAN Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)
    2.9 India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030)

3 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies Competitive Analysis
    3.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in 2023
        3.2.3 Global Concentration Ratios (CR8) for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in 2023
    3.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Evaluation Quadrant
    3.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Overall Company Footprint Analysis
        3.4.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Region Footprint
        3.4.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Type Footprint
        3.4.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers & Acquisitions Activity

4 United States VS China VS Rest of World (by Headquarter Location)
    4.1 United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Comparison
        4.2.1 United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies and Market Share, 2019-2024
        4.3.1 United States Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, (2019-2024)
    4.4 China Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Market Share, 2019-2024
        4.4.1 China Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, (2019-2024)
    4.5 Rest of World Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Headquarters (Province, Country)
        4.5.2 Rest of World Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2024)

5 Market Analysis by Type
    5.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Solid Dosage Form
        5.2.2 Liquid Dosage Form
    5.3 Market Segment by Type
        5.3.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2019-2024)
        5.3.2 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2025-2030)
        5.3.3 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Type (2025-2030)

6 Market Analysis by Application
    6.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Digestive System Diseases
        6.2.2 Immune System Diseases
        6.2.3 Metabolic Diseases
        6.2.4 Other
    6.3 Market Segment by Application
        6.3.1 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2019-2024)
        6.3.2 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2025-2030)
        6.3.3 World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Application (2019-2030)

7 Company Profiles
    7.1 Lallemand Health Solutions
        7.1.1 Lallemand Health Solutions Details
        7.1.2 Lallemand Health Solutions Major Business
        7.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Lallemand Health Solutions Recent Developments/Updates
        7.1.6 Lallemand Health Solutions Competitive Strengths & Weaknesses
    7.2 Wacker Chemie AG
        7.2.1 Wacker Chemie AG Details
        7.2.2 Wacker Chemie AG Major Business
        7.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Wacker Chemie AG Recent Developments/Updates
        7.2.6 Wacker Chemie AG Competitive Strengths & Weaknesses
    7.3 Biose Industrie
        7.3.1 Biose Industrie Details
        7.3.2 Biose Industrie Major Business
        7.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Biose Industrie Recent Developments/Updates
        7.3.6 Biose Industrie Competitive Strengths & Weaknesses
    7.4 List Biological Labs, Inc.
        7.4.1 List Biological Labs, Inc. Details
        7.4.2 List Biological Labs, Inc. Major Business
        7.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 List Biological Labs, Inc. Recent Developments/Updates
        7.4.6 List Biological Labs, Inc. Competitive Strengths & Weaknesses
    7.5 NIZO
        7.5.1 NIZO Details
        7.5.2 NIZO Major Business
        7.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 NIZO Recent Developments/Updates
        7.5.6 NIZO Competitive Strengths & Weaknesses
    7.6 SGS (Quay Pharmaceuticals)
        7.6.1 SGS (Quay Pharmaceuticals) Details
        7.6.2 SGS (Quay Pharmaceuticals) Major Business
        7.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 SGS (Quay Pharmaceuticals) Recent Developments/Updates
        7.6.6 SGS (Quay Pharmaceuticals) Competitive Strengths & Weaknesses
    7.7 Assembly Biosciences, Inc.
        7.7.1 Assembly Biosciences, Inc. Details
        7.7.2 Assembly Biosciences, Inc. Major Business
        7.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Assembly Biosciences, Inc. Recent Developments/Updates
        7.7.6 Assembly Biosciences, Inc. Competitive Strengths & Weaknesses
    7.8 Recipharm (Arranta Bio)
        7.8.1 Recipharm (Arranta Bio) Details
        7.8.2 Recipharm (Arranta Bio) Major Business
        7.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Recipharm (Arranta Bio) Recent Developments/Updates
        7.8.6 Recipharm (Arranta Bio) Competitive Strengths & Weaknesses
    7.9 Bacthera (Novonesis+Lonza)
        7.9.1 Bacthera (Novonesis+Lonza) Details
        7.9.2 Bacthera (Novonesis+Lonza) Major Business
        7.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Bacthera (Novonesis+Lonza) Recent Developments/Updates
        7.9.6 Bacthera (Novonesis+Lonza) Competitive Strengths & Weaknesses
    7.10 Smaltis
        7.10.1 Smaltis Details
        7.10.2 Smaltis Major Business
        7.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Smaltis Recent Developments/Updates
        7.10.6 Smaltis Competitive Strengths & Weaknesses
    7.11 Lonza
        7.11.1 Lonza Details
        7.11.2 Lonza Major Business
        7.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Lonza Recent Developments/Updates
        7.11.6 Lonza Competitive Strengths & Weaknesses
    7.12 vermicon AG
        7.12.1 vermicon AG Details
        7.12.2 vermicon AG Major Business
        7.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
        7.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 vermicon AG Recent Developments/Updates
        7.12.6 vermicon AG Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Chain
    8.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Upstream Analysis
    8.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Midstream Analysis
    8.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Table 2. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
 Table 3. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
 Table 4. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Region (2019-2024), (by Headquarter Location)
 Table 5. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Region (2025-2030), (by Headquarter Location)
 Table 6. Major Market Trends
 Table 7. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
 Table 8. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 9. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Forecast by Region (2025-2030) & (USD Million)
 Table 10. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Player (2019-2024) & (USD Million)
 Table 11. Revenue Market Share of Key Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players in 2023
 Table 12. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Rank of Major Player, Based on Revenue in 2023
 Table 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Evaluation Quadrant
 Table 14. Head Office of Key Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players
 Table 15. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Type Footprint
 Table 16. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Application Footprint
 Table 17. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Mergers & Acquisitions Activity
 Table 18. United States VS China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 19. United States VS China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 20. United States Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Headquarters (States, Country)
 Table 21. United States Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, (2019-2024) & (USD Million)
 Table 22. United States Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share (2019-2024)
 Table 23. China Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Headquarters (Province, Country)
 Table 24. China Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, (2019-2024) & (USD Million)
 Table 25. China Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share (2019-2024)
 Table 26. Rest of World Based Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies, Headquarters (Province, Country)
 Table 27. Rest of World Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2024) & (USD Million)
 Table 28. Rest of World Based Companies Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share (2019-2024)
 Table 29. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Table 30. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Value by Type (2019-2024) & (USD Million)
 Table 31. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2025-2030) & (USD Million)
 Table 32. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Table 33. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2019-2024) & (USD Million)
 Table 34. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2025-2030) & (USD Million)
 Table 35. Lallemand Health Solutions Basic Information, Manufacturing Base and Competitors
 Table 36. Lallemand Health Solutions Major Business
 Table 37. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 38. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 39. Lallemand Health Solutions Recent Developments/Updates
 Table 40. Lallemand Health Solutions Competitive Strengths & Weaknesses
 Table 41. Wacker Chemie AG Basic Information, Manufacturing Base and Competitors
 Table 42. Wacker Chemie AG Major Business
 Table 43. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 44. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 45. Wacker Chemie AG Recent Developments/Updates
 Table 46. Wacker Chemie AG Competitive Strengths & Weaknesses
 Table 47. Biose Industrie Basic Information, Manufacturing Base and Competitors
 Table 48. Biose Industrie Major Business
 Table 49. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 50. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 51. Biose Industrie Recent Developments/Updates
 Table 52. Biose Industrie Competitive Strengths & Weaknesses
 Table 53. List Biological Labs, Inc. Basic Information, Manufacturing Base and Competitors
 Table 54. List Biological Labs, Inc. Major Business
 Table 55. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 56. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 57. List Biological Labs, Inc. Recent Developments/Updates
 Table 58. List Biological Labs, Inc. Competitive Strengths & Weaknesses
 Table 59. NIZO Basic Information, Manufacturing Base and Competitors
 Table 60. NIZO Major Business
 Table 61. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 62. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 63. NIZO Recent Developments/Updates
 Table 64. NIZO Competitive Strengths & Weaknesses
 Table 65. SGS (Quay Pharmaceuticals) Basic Information, Manufacturing Base and Competitors
 Table 66. SGS (Quay Pharmaceuticals) Major Business
 Table 67. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 68. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 69. SGS (Quay Pharmaceuticals) Recent Developments/Updates
 Table 70. SGS (Quay Pharmaceuticals) Competitive Strengths & Weaknesses
 Table 71. Assembly Biosciences, Inc. Basic Information, Manufacturing Base and Competitors
 Table 72. Assembly Biosciences, Inc. Major Business
 Table 73. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 74. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 75. Assembly Biosciences, Inc. Recent Developments/Updates
 Table 76. Assembly Biosciences, Inc. Competitive Strengths & Weaknesses
 Table 77. Recipharm (Arranta Bio) Basic Information, Manufacturing Base and Competitors
 Table 78. Recipharm (Arranta Bio) Major Business
 Table 79. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 80. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 81. Recipharm (Arranta Bio) Recent Developments/Updates
 Table 82. Recipharm (Arranta Bio) Competitive Strengths & Weaknesses
 Table 83. Bacthera (Novonesis+Lonza) Basic Information, Manufacturing Base and Competitors
 Table 84. Bacthera (Novonesis+Lonza) Major Business
 Table 85. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 86. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 87. Bacthera (Novonesis+Lonza) Recent Developments/Updates
 Table 88. Bacthera (Novonesis+Lonza) Competitive Strengths & Weaknesses
 Table 89. Smaltis Basic Information, Manufacturing Base and Competitors
 Table 90. Smaltis Major Business
 Table 91. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 92. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 93. Smaltis Recent Developments/Updates
 Table 94. Smaltis Competitive Strengths & Weaknesses
 Table 95. Lonza Basic Information, Manufacturing Base and Competitors
 Table 96. Lonza Major Business
 Table 97. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 98. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 99. Lonza Recent Developments/Updates
 Table 100. Lonza Competitive Strengths & Weaknesses
 Table 101. vermicon AG Basic Information, Manufacturing Base and Competitors
 Table 102. vermicon AG Major Business
 Table 103. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Services
 Table 104. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 105. vermicon AG Recent Developments/Updates
 Table 106. vermicon AG Competitive Strengths & Weaknesses
 Table 107. Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Upstream (Raw Materials)
 Table 108. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Typical Customers


List of Figures
 Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Picture
 Figure 2. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Total Revenue: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Total Revenue (2019-2030) & (USD Million)
 Figure 4. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Figure 5. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Region (2019-2030), (by Headquarter Location)
 Figure 6. United States Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 7. China Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 8. Europe Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 9. Japan Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 10. South Korea Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 11. ASEAN Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 12. India Based Company Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 13. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers
 Figure 14. Factors Affecting Demand
 Figure 15. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 16. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 17. United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 18. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 19. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 20. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 21. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 22. ASEAN Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 23. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 24. Producer Shipments of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Player Revenue ($MM) and Market Share (%): 2023
 Figure 25. Global Four-firm Concentration Ratios (CR4) for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Markets in 2023
 Figure 26. Global Four-firm Concentration Ratios (CR8) for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Markets in 2023
 Figure 27. United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Figure 30. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Type in 2023
 Figure 31. Solid Dosage Form
 Figure 32. Liquid Dosage Form
 Figure 33. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Type (2019-2030)
 Figure 34. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Figure 35. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Application in 2023
 Figure 36. Digestive System Diseases
 Figure 37. Immune System Diseases
 Figure 38. Metabolic Diseases
 Figure 39. Other
 Figure 40. World Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Market Share by Application (2019-2030)
 Figure 41. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industrial Chain
 Figure 42. Methodology
 Figure 43. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Lallemand Health Solutions
Wacker Chemie AG
Biose Industrie
List Biological Labs, Inc.
NIZO
SGS (Quay Pharmaceuticals)
Assembly Biosciences, Inc.
Recipharm (Arranta Bio)
Bacthera (Novonesis+Lonza)
Smaltis
Lonza
vermicon AG

Related Reports

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 15 Nov 2024

date Service & Software

According to our (Global Info Research) latest study, the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size was valued at US$ 146 million in 2023 and is forecast to a readjusted size of USD 553 million by 2030 with a CAGR of 19.0% during review period.

Product Tags

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service

soil fertility

Image High Dynamic

Building Energy Modeling

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>